Compare BioSig Technologies, Inc. with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.14%
0%
-34.14%
6 Months
-32.51%
0%
-32.51%
1 Year
182.08%
0%
182.08%
2 Years
123.13%
0%
123.13%
3 Years
200.38%
0%
200.38%
4 Years
-81.77%
0%
-81.77%
5 Years
-93.86%
0%
-93.86%
BioSig Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
7.13%
EBIT to Interest (avg)
-32.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.35
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
48.90%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
73.83
EV to EBIT
-15.83
EV to EBITDA
-16.00
EV to Capital Employed
-196.40
EV to Sales
196.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-458.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 4 Schemes (4.68%)
Foreign Institutions
Held by 11 Foreign Institutions (0.85%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.80
-3.00
-560.00%
Interest
0.00
0.00
Exceptional Items
-0.00
0.20
-100.00%
Consolidate Net Profit
-20.40
-2.80
-628.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -628.57% vs -154.55% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.40
-28.20
56.03%
Interest
0.00
0.00
Exceptional Items
2.30
-0.20
1,250.00%
Consolidate Net Profit
-10.30
-28.70
64.11%
Operating Profit Margin (Excl OI)
-315,225.00%
-1,584,000.00%
1,26,877.50%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 64.11% vs -5.13% in Dec 2023
About BioSig Technologies, Inc. 
BioSig Technologies, Inc.
Pharmaceuticals & Biotechnology
BioSig Technologies, Inc. is a commercial-stage medical device company. The Company is commercializing biomedical signal processing technology platform to extract information from physiologic signals. The Company focuses on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The Company is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The PURE EP System is a signal acquisition and processing technology.
Company Coordinates 
Company Details
54 WILTON ROAD, 2ND FLOOR , WESTPORT CT : 06880
Registrar Details






